Icatibant

Drugs

Volumn 70, Issue 1, 2010, Pages 73-81

  Deeks, Emma D ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ICATIBANT; TRANEXAMIC ACID;

ABDOMINAL DISEASE; ABDOMINAL PAIN; ANGIONEUROTIC EDEMA; AREA UNDER THE CURVE; ASTHENIA; CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; DISEASE SEVERITY; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG STRUCTURE; DRUG TOLERABILITY; HEADACHE; HUMAN; INJECTION SITE BURNING; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; INJECTION SITE WARMTH; LARYNX DISORDER; LIVER FUNCTION TEST; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NONHUMAN; NOSE CONGESTION; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; RASH; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DISEASE; SYMPTOMATOLOGY; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

ADULT; ANGIOEDEMAS, HEREDITARY; BRADYKININ; BRONCHODILATOR AGENTS; CALCIUM CHANNEL BLOCKERS; CHEMISTRY, PHARMACEUTICAL; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; META-ANALYSIS AS TOPIC; PAIN MEASUREMENT; PAIN, POSTOPERATIVE; RECEPTOR, BRADYKININ B2; SEROTONIN AGONISTS; TOOTH EXTRACTION; TREATMENT OUTCOME;

EID: 73349141707     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11204500-000000000-00000     Document Type: Review

References (21)

1. Bowen T, Cicardi M, Bork K, et al. Hereditary angiodema: a current state-of-the-art review, VII-Canadian Hungarian 2007 international consensus algorithm for the diagnosis, therapy, and management of hereditary angioedema. Ann Allergy Asthma Immunol 2008 Jan; 100 (1 Suppl. 2): S30-40
2. Reshef A, Leibovich I, Goren A. Hereditary angioedema: new hopes for an orphan disease. Isr Med Assoc J 2008 Dec; 10 (12): 850-855
3. Davis AE. New treatments addressing the pathophysiology of hereditary angioedema. Clin Mol Allergy 2008 Apr 14; 6 (2)
4. Zuraw BL. Hereditary angioedema. New Eng J Med 2008 Sep 4; 359 (10): 1027-1036
5. Longhurst HJ. Emergency treatment of acute attacks in hereditary angioedema due to C1 inhibitor deficiency: what is the evidence? Int J Clin Pract 2005 May; 59 (5): 594-599
6. Cugno M, Cicardi M, Bottasso B, et al. Activation of the coagulation cascade in C1-inhibitor deficiencies. Blood 1997 May 1; 89 (9): 3213-3218
7. Gompels MM, Lock RJ, Abinun M, et al. C1 inhibitor deficiency: consensus document [published erratum appears in Clin Exp Immunol 2005; 141 (1): 189-90]. Clin Exp Immunol 2005; 139 (3): 379-394
8. Frank MM, Jiang H. New therapies for hereditary angioedema: disease outlook changes dramatically. J Allergy Clin Immunol 2008 Jan; 121 (1): 272-280
9. Jerini AG. Firazyr 30mg solution for injection in pre-filled syringe: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandocs/ PDFs/EPAR/firazyr/emea-combined-h889en.pdf [Accessed 2009 Sep 24]
10. Hock FJ, Wirth K, Albus U, et al. Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br J Pharmacol 1991; 102: 769-773
11. Wirth K, Hock FJ, Albus U, et al. Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies. Br J Pharmacol 1991; 102: 774-777
12. Han ED, MacFarlane RC, Mulligan AN, et al. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest 2002 Apr; 109 (8): 1057-1063
13. Cockcroft JR, Chowienczyk PJ, Brett SE, et al. Inhibition of bradykinin-induced vasodilation in human forearm vas-culature by icatibant, a potent B2-receptor antagonist. Br J Clin Pharmacol 1994; 38: 317-322
14. Brown NJ, Gainer JV, Murphey LJ, et al. Bradykinin stimulates tissue plasminogen activator release from human forearm vasculature through B2 receptor-dependent, NO, and cyclooxygenase-independent pathway. Circulation 2000 Oct 18; 102 (18): 2190-2196
15. European Medicines Agency. CHMP assessment report for Firazyr [online]. Available from URL: http://www.emea. europa.eu/humandocs/PDFs/EPAR/firazyr/H- 899-en6.pdf [Accessed 2009 Sep 23]
16. Wagner F, Rosenkranz B, Knolle J. Absolute bioavailability of subcutaneously administered icatibant, a selective and potent bradykinin B2 receptor antagonist [abstract no. 1071]. J Allergy Clin Immunol 2007 Jan; 119 (1 Suppl.): S274
17. Bork K, Frank J, Grundt B, et al. Treatment of acute edema attacks in hereditary angioedema with a bradykinin re-ceptor-2 antagonist (icatibant). J Allergy Clin Immunol 2007 Jun; 119 (6): 1497-1503
18. Riedl M. Icatibant, a selective bradykinin B2 receptor antagonist, proves effective and safe in treating the symptoms of hereditary angioedema (HAE) attacks [abstract no. 398]. J Allergy Clin Immunol 2008 Feb; 121 (2): S103
19. Malbran A. Successful treatment of 103 attacks of hereditary angioedema (HAE) with bradykinin B2 receptor antagonist icatibant [abstract no. 395]. J Allergy Clin Immunol 2008 Feb; 121 (2): S102
20. US National Institutes of Health. Providing information regarding some clinical trials that are completed. [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2009 Sep 25]
21. Staubach P, Bork K. Safety evaluation of icatibant, a selective bradykinin B2 receptor antagonist used in hereditary angioedema due to C1 inhibitor deficiency [abstract no. 376]. J Allergy Clin Immunol 2009 Feb; 123 (2 Suppl.): S100